Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry
Patients with VEXAS syndrome required high-dose glucocorticoids to reduce disease activity, and complications-such as malignancy, thrombosis, and infection-occurred frequently within a short observation period.
Authors
- Dai Kishida (ORCID: https://orcid.org/0000-0001-8309-7984)
- Yohei Kirino (ORCID: https://orcid.org/0000-0002-9488-661X)
- Ryo Rokutanda (ORCID: https://orcid.org/0000-0001-5966-6403)
- Nobuhiro Oda (ORCID: https://orcid.org/0000-0003-3967-6414)
- Kohei Tsujimoto (ORCID: https://orcid.org/0000-0001-6958-2983)
- Yuichiro Fujieda (ORCID: https://orcid.org/0000-0003-4705-341X)
- Takako Miyamae (ORCID: https://orcid.org/0000-0002-0568-1496)
- Yutaka Inaba (ORCID: https://orcid.org/0000-0003-2030-467X)
- Anna Hasegawa
- Hideaki Nakajima (ORCID: https://orcid.org/0000-0002-8967-4954)
- Tomoya Watanabe (ORCID: https://orcid.org/0000-0002-6654-6175)
- Ken Nagahata (ORCID: https://orcid.org/0000-0002-5233-8308)
- Toshimasa Shimizu (ORCID: https://orcid.org/0000-0003-0036-2039)
- Hiroaki Ida (ORCID: https://orcid.org/0000-0003-0295-0301)
- Kiyoshi Migita (ORCID: https://orcid.org/0000-0003-1339-5622)
- Osamu Ohara (ORCID: https://orcid.org/0000-0002-3328-9571)
- Koji Mishima (ORCID: https://orcid.org/0000-0003-4033-3216)
- Tomohiro Tsuji (ORCID: https://orcid.org/0000-0002-1237-7062)
- Ryuta Nishikomori (ORCID: https://orcid.org/0000-0002-9407-6158)
- Motoaki Shiratsuchi (ORCID: https://orcid.org/0000-0002-0403-0122)
- Kensaku Takatsuki (ORCID: https://orcid.org/0000-0001-7019-0573)
- Kei Ikeda (ORCID: https://orcid.org/0000-0003-0574-9611)
- Tatsuya Atsumi (ORCID: https://orcid.org/0000-0001-5657-962X)
- Yukie Yamaguchi (ORCID: https://orcid.org/0000-0002-0297-6627)
- Hiroshi Kobayashi (ORCID: https://orcid.org/0000-0002-0748-3784)
- Tomoyuki Asano
- Ayaka Maeda (ORCID: https://orcid.org/0000-0002-1102-0475)
- Atsushi Kawakami (ORCID: https://orcid.org/0000-0002-1512-8782)
- Daisuke Kobayashi (ORCID: https://orcid.org/0000-0002-0384-8678)
- Kazuki Tanaka (ORCID: https://orcid.org/0009-0000-4683-5968)
- Yuji Miyoshi (ORCID: https://orcid.org/0009-0001-4981-6583)
- Yoichi Takeuchi (ORCID: https://orcid.org/0000-0001-7031-0651)
- Yukiko Hidaka
Institutions
- Kurume University (JP)
- Fukushima Medical University (JP)
- Shinshu University (JP)
- Sapporo Medical University (JP)
- Wakayama Medical University (JP)
- Hokkaido University (JP)
- Maebashi Red Cross Hospital (JP)
- Tokyo Medical University Hachioji Medical Center (JP)
- Tokyo Women's Medical University Hospital (JP)
- Kameda Medical Center (JP)
- Matsuyama Red Cross Hospital (JP)
- Niigata University Medical and Dental Hospital (JP)
- Fujieda Municipal General Hospital (JP)
- Immune Regulation (United Kingdom) (GB)
- Aso Iizuka Hospital (JP)
- Kazusa DNA Research Institute (JP)
- Tokyo Metropolitan Tama Medical Center (JP)
- Genomics (United Kingdom) (GB)
- Nagasaki University (JP)
- Niigata University (JP)
- Dokkyo Medical University (JP)
- Yokohama City University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1093/rheumatology/keae530
- Citations
- 20
- Primary Topic
- Otitis Media and Relapsing Polychondritis
- Type
- article
- Field-Weighted Citation Impact
- 9.40
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Japan Agency for Medical Research and Development
- Kissei
- Nippon Shinyaku
- Celltrion
- Ministry of Health, Labour and Welfare
- Eisai
- Wakayama Medical University
- Astellas Pharma
- Swedish Orphan Biovitrum
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Daiichi Sankyo Europe